Evaluation of nepafenac in prevention of macular edema following cataract surgery in patients with diabetic retinopathy.

ABSTRACT:

Background

The purpose of this study was to evaluate nepafenac ophthalmic suspension 0.1% (Nevanac(®); Alcon Research Ltd) in the prevention of macular edema following cataract surgery in diabetic retinopathy patients.

Methods

This was a multicenter, randomized, double-masked, vehicle-controlled study of 263 adult diabetic patients with nonproliferative diabetic retinopathy requiring cataract surgery. Patients were randomized (1:1) to instill nepafenac or vehicle three times daily beginning 1 day prior to surgery through day 90. Efficacy included the percentage of patients who developed macular edema (≥30% increase in central subfield macular thickness from baseline) and the percentage of patients with decreases of more than five letters in best-corrected visual acuity from

SUBMITTER: Singh R 

PROVIDER: S-EPMC3422154 | biostudies-literature | 2012

REPOSITORIES: biostudies-literature